JP2003522145A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522145A5
JP2003522145A5 JP2001557560A JP2001557560A JP2003522145A5 JP 2003522145 A5 JP2003522145 A5 JP 2003522145A5 JP 2001557560 A JP2001557560 A JP 2001557560A JP 2001557560 A JP2001557560 A JP 2001557560A JP 2003522145 A5 JP2003522145 A5 JP 2003522145A5
Authority
JP
Japan
Prior art keywords
nicotine
methylpyrazole
piperidino
dichlorophenyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2001557560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522145A (ja
Filing date
Publication date
Priority claimed from FR0001682A external-priority patent/FR2804604B1/fr
Application filed filed Critical
Publication of JP2003522145A publication Critical patent/JP2003522145A/ja
Publication of JP2003522145A5 publication Critical patent/JP2003522145A5/ja
Ceased legal-status Critical Current

Links

JP2001557560A 2000-02-09 2001-02-07 セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用 Ceased JP2003522145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/01682 2000-02-09
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009217269A Division JP2010018622A (ja) 2000-02-09 2009-09-18 セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用

Publications (2)

Publication Number Publication Date
JP2003522145A JP2003522145A (ja) 2003-07-22
JP2003522145A5 true JP2003522145A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=8846875

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001557560A Ceased JP2003522145A (ja) 2000-02-09 2001-02-07 セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用
JP2009217269A Withdrawn JP2010018622A (ja) 2000-02-09 2009-09-18 セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009217269A Withdrawn JP2010018622A (ja) 2000-02-09 2009-09-18 セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用

Country Status (32)

Country Link
US (2) US6930122B2 (cg-RX-API-DMAC7.html)
EP (1) EP1257275B1 (cg-RX-API-DMAC7.html)
JP (2) JP2003522145A (cg-RX-API-DMAC7.html)
CN (1) CN1250220C (cg-RX-API-DMAC7.html)
AR (1) AR028505A1 (cg-RX-API-DMAC7.html)
AT (1) ATE292467T1 (cg-RX-API-DMAC7.html)
AU (1) AU781827B2 (cg-RX-API-DMAC7.html)
BG (2) BG110386A (cg-RX-API-DMAC7.html)
BR (1) BR0108126A (cg-RX-API-DMAC7.html)
CA (1) CA2397262C (cg-RX-API-DMAC7.html)
CZ (1) CZ296685B6 (cg-RX-API-DMAC7.html)
DE (1) DE60109903T2 (cg-RX-API-DMAC7.html)
DK (1) DK1257275T3 (cg-RX-API-DMAC7.html)
EE (1) EE04836B1 (cg-RX-API-DMAC7.html)
ES (1) ES2240416T3 (cg-RX-API-DMAC7.html)
FR (1) FR2804604B1 (cg-RX-API-DMAC7.html)
HU (1) HU225328B1 (cg-RX-API-DMAC7.html)
IL (1) IL150710A0 (cg-RX-API-DMAC7.html)
IS (1) IS6450A (cg-RX-API-DMAC7.html)
MX (1) MXPA02007766A (cg-RX-API-DMAC7.html)
NO (1) NO324521B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ519924A (cg-RX-API-DMAC7.html)
PL (1) PL201685B1 (cg-RX-API-DMAC7.html)
PT (1) PT1257275E (cg-RX-API-DMAC7.html)
RS (1) RS50404B (cg-RX-API-DMAC7.html)
RU (1) RU2257207C2 (cg-RX-API-DMAC7.html)
SI (1) SI1257275T1 (cg-RX-API-DMAC7.html)
SK (1) SK284952B6 (cg-RX-API-DMAC7.html)
TW (1) TWI243677B (cg-RX-API-DMAC7.html)
UA (1) UA72783C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001058450A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200205317B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
AU2002356039A1 (en) 2001-08-13 2003-03-03 Honeywell International Inc. Methods of conducting wafer level burn-in of electronic devices
JP2005533748A (ja) 2002-03-08 2005-11-10 シグナル ファーマシューティカルズ,インコーポレイテッド 増殖性障害および癌を治療、予防、または管理するための併用療法
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク エンド カムパニー インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
JP2005531520A (ja) 2002-03-28 2005-10-20 メルク エンド カムパニー インコーポレーテッド 置換2,3−ジフェニルピリジン類
WO2003086288A2 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
CA2499497A1 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2004058145A2 (en) 2002-12-19 2004-07-15 Merck & Co., Inc. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CA2526103A1 (en) * 2003-05-20 2004-12-29 Bob M. Ii Moore Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CA2543882A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
MX2007000491A (es) 2004-07-12 2007-03-28 Cadila Healthcare Ltd Nuevos compuestos heterociclicos.
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
NZ569814A (en) * 2006-01-18 2011-10-28 Schering Corp Cannibinoid receptor modulators
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
WO2008046905A1 (en) * 2006-10-20 2008-04-24 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
WO2009005671A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
EP2170846A2 (en) * 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防/改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Similar Documents

Publication Publication Date Title
JP2003522145A5 (cg-RX-API-DMAC7.html)
RU2002118309A (ru) Применение антагониста центральных каннабиноидных рецепторов для приготовления лекарств, предназначенных для облегчения прекращения курения
CA2477301A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
HUP0001894A2 (hu) N-Piperidino-3-pirazolkarboxamid-származékot, sóját vagy szolvátját tartalmazó orálisan adagolható gyógyszerkészítmény
PE20081649A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
HRP20030249A2 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
CA2376226A1 (en) New formulation
LT2000064A (en) Flash-melt oral dosage formulation
TNSN04095A1 (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
JP2019536812A5 (cg-RX-API-DMAC7.html)
WO2002016312A3 (de) NEUE VERBINDUNGEN, DIE FAKTOR Xa-AKTIVITÄT INHIBIEREN
DE50109650D1 (de) Topische behandlung bei der mastalgie
CA2473202A1 (en) Pharmaceutical composition for regeneration of cirrhotic liver
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
EA200800966A1 (ru) Новая композиция, содержащая росиглитазон и другое противодиабетическое средство
WO2004037228A8 (en) Sustained release compositions containing alfuzosin
HRP20020989B1 (hr) Enantiomer 1,2-aneliranog kinolina koji inhibira farnezil transferazu
KR20070112266A (ko) 칸나비노이드 수용체 길항제 화합물과 항정신병제의조합물을 함유하는 제약 조성물
EP1064967A3 (en) 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine
US20190336636A1 (en) Dissolvable effervescent toilet deodorizer and method of use